Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study
Intercept says it received approval from the FDA.
Acknowledging slowing enrollment in its phase III study of obeticholic acid in fatty liver disease, Intercept Pharmaceuticals (ICPT) - Get Report said it will make changes to the study to reach an interim analysis faster and to lower the definition of clinical success.
This article was written by a staff member of TheStreet.
